{"entity":{"id":"nct06033586","kind":"trial","name":"Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera","aka":["THRIVE"],"tldr":"A phase 3 trial of Rusfertide in myeloproliferative neoplasms, run by Protagonist Therapeutics, Inc., active and no longer recruiting.","summary":"Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera is a phase 3 interventional study registered as NCT06033586 by Protagonist Therapeutics, Inc., with 46 participants enrolled, started 2024-01-22 and due to reach its primary completion in 2026-04-01. Interventions recorded: Open-label rusfertide.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06033586","url":"https://clinicaltrials.gov/study/NCT06033586"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":["peptide-drug-conjugate"],"targets":[],"drugs":["rusfertide"],"companies":["protagonist-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06033586","phase":"3","setting":"An Extension Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera (THRIVE)","sponsor":"Protagonist Therapeutics, Inc.","participation":[{"nct":"NCT06033586","source":"https://clinicaltrials.gov/study/NCT06033586","fetchedAt":"2026-10-07T16:54:07.437Z","studySha256":"68990e902f97a8baa51b31a4d16dc23c34cedbc9f930a3b2ede59dff46b597a4","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-08-06","leadSponsor":"Protagonist Therapeutics, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":46,"enrolmentType":"ACTUAL","siteCount":1,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2024-01-22","startedType":"actual","enrolled":46,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06033586/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"technology":[{"id":"peptide-drug-conjugate","kind":"technology","name":"Peptide-drug & small-molecule-drug conjugates","route":"/technologies/peptide-drug-conjugate/"}],"drug":[{"id":"rusfertide","kind":"drug","name":"Rusfertide","route":"/drugs/rusfertide/"}],"company":[{"id":"protagonist-therapeutics","kind":"company","name":"Protagonist Therapeutics","route":"/companies/protagonist-therapeutics/"}]}}